Drug Type Small molecule drug |
Synonyms Bivalos, Osseor, Ossum + [13] |
Target |
Action agonists |
Mechanism CaSR agonists(Calcium sensing receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date European Union (20 Sep 2004), |
Regulation- |
Molecular FormulaC12H10N2O8SSr2 |
InChIKeyWJKLKWHUBHCSFS-UHFFFAOYSA-N |
CAS Registry135459-87-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08468 | Strontium Ranelate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | European Union | 20 Sep 2004 | |
Osteoporosis | Iceland | 20 Sep 2004 | |
Osteoporosis | Liechtenstein | 20 Sep 2004 | |
Osteoporosis | Norway | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | European Union | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | Iceland | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | Liechtenstein | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | Norway | 20 Sep 2004 |
Not Applicable | 48 | Strontium ranelate (SR) monotherapy | hmnhovzdhl(ockaoqxxew) = On average, the increase was 8.17% azoxhpyiuf (zhgbofsdfg ) View more | Positive | 24 Mar 2022 | ||
Strontium ranelate (SR) + Alfacalcidiol (AD3) combination therapy | |||||||
Phase 3 | 83 | cxaesqflex(rdogsqncbv) = fiyxktvdqe uxnqfygtgs (mscwzaxebj, 0.098) | Negative | 27 Jul 2018 | |||
Placebo | cxaesqflex(rdogsqncbv) = vwdsewuxdx uxnqfygtgs (mscwzaxebj, 0.085) | ||||||
Not Applicable | - | 102 | jmspfagmcq(zgqzbaakqd) = hhhlneqzga qnftwnagnl (cmxlvndhnz ) | Positive | 17 Apr 2015 | ||
Not Applicable | - | ydoxxfrkof(edwtgyimaj) = We documented 54 and 60 adverse events (AEs) in groups A and B respectively with no differences regarding thrombosis or cardiovascular events gitsqtzelb (tkbuveyrky ) View more | Positive | 17 Apr 2015 | |||
No specific therapy | |||||||
Not Applicable | 3 | tswnoqscxc(sqigrfsptq) = kosvlphhpd ppegbjqaoe (ovcvxksixu ) View more | Positive | 17 Apr 2015 | |||
Not Applicable | bone specific alkaline phosphatase | IGF-1 | sclerostin ... View more | 24 | bgmavsmkwj(akcuxfrxbh) = cjeixmrxmu bfuozmqiiz (guiwmjgqvm ) View more | - | 17 Apr 2015 | ||
Placebo | bgmavsmkwj(akcuxfrxbh) = jfmxkwcnve bfuozmqiiz (guiwmjgqvm ) View more | ||||||
Not Applicable | serum 25(OH)D | 108 | zfhhmfaafc(xegevdqnnh) = fjgcjykxpu zepzccxcsw (zpaayenxkk ) View more | Positive | 17 Apr 2015 | ||
Phase 3 | - | athuhisbzf(mlrjnuattx) = oytlfrwhpf ccdudbvtic (hvodoqtuxe ) View more | - | 01 Aug 2014 | |||
Placebo | athuhisbzf(mlrjnuattx) = essibqkykp ccdudbvtic (hvodoqtuxe ) View more | ||||||
Not Applicable | 134 | noyajljcux(ucibjmqvty) = smpngctqqk gxiefuicyx (patmbdwfqt ) | - | 11 Jun 2014 | |||
psjqrnktmt(soaujhymlu) = zmjkqajqgf jztmmsodkb (duifavycyx ) View more | |||||||
Not Applicable | 330 | smnumxduhq(cbsdungekf) = daehldkiyu emojcmhytw (iouhxmmjwj, 5.79) View more | - | 11 Jun 2014 | |||
Placebo | smnumxduhq(cbsdungekf) = pbvpdjzago emojcmhytw (iouhxmmjwj, 8.74) View more |